[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@masonat7 Mason
Mason posts on X about $nams, $amgn, $5b, amgn the most. They currently have XX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX +16,017%
- X Month XXXXX +177%
- X Months XXXXXX +297%
- X Year XXXXXX +1,449%
Mentions: X #
- X Week X +200%
- X Month X no change
- X Months XX +92%
- X Year XX +250%
Followers: XX #
- X Week XX +13%
- X Month XX +11%
- X Months XX +300%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks finance
Social topic influence $nams #4, $amgn, $5b, amgn, $espr, approved, insurance, combo, drugs
Top assets mentioned NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Amgen, Inc. (AMGN)
Top Social Posts #
Top posts by engagements in the last XX hours
"@PersimmonTI You think $AMGN would pay $5B+ for $NAMS after they originally sold off obicetrapib to NAMS for much less"
X Link @masonat7 2025-10-13T18:37Z XX followers, 4799 engagements
"$NAMS reminder that obicetrapib is not like other CETP inhibitors. Every other CETPi increased hs-CRP. Obicetrapib appears to modestly decrease hs-CRP"
X Link @masonat7 2025-10-13T16:45Z XX followers, XXX engagements
"@SnupSnus @PCM_bio @PersimmonTI There's going to be a big push to treat lp(a) if/when these lp(a) drugs get approved but insurance might only cover for 150nmol (similar to trial population) even though risk starts to increase at 50nmol. $NAMS is studying combo with repatha on lp(a) in the 50-150 range"
X Link @masonat7 2025-10-14T20:55Z XX followers, XXX engagements